Valuation: Alkermes plc

Market Cap 9.05B 7.94B 7.33B 6.77B 12.83B 866B 13.09B 88.09B 34.23B 424B 33.98B 33.24B 1,472B P/E 2026 *
-142x
P/E 2027 * 92x
Enterprise Value 10.01B 8.78B 8.11B 7.49B 14.2B 958B 14.48B 97.44B 37.86B 469B 37.59B 36.77B 1,628B EV / Sales 2026 *
5.53x
EV / Sales 2027 * 5.16x
Free-Float
89.39%
Yield 2026 *
-
Yield 2027 * -
1 day-1.68%
1 week+4.97%
Current month+3.62%
1 month+27.89%
3 months+56.14%
6 months+83.41%
Current year+94.03%
1 week 53.41
Extreme 53.41
55.67
1 month 43.34
Extreme 43.34
55.67
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 64 31/01/1991
Director of Finance/CFO 53 14/09/2025
Chief Tech/Sci/R&D Officer 58 29/05/2017
Director TitleAgeSince
Chairman 64 31/08/2011
Director/Board Member 74 25/05/2016
Director/Board Member 63 29/03/2018
Date Insider Type Main position Quantity % Market Cap.
07-05Sell

Compliance Officer

-2,034 0.0012%
06-30Fiscal year

Chief Technology Officer

19,000 0.0114%
06-11Sell

Director

-2,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-1.68%+4.97%+84.79%+81.69% 9.05B
+0.77%+2.34%+2.70%+9.31% 49.42B
-0.36%+1.21%+420.77%+619.10% 40.34B
-2.13%+0.29%+23.91%-6.01% 34.01B
-2.29%+3.83%+23.48%+59.26% 33.56B
-0.79%+1.32%+5.78%+36.42% 26.84B
+3.82%+3.51% - - 17.22B
-2.62%-2.13%+64.96%+125.87% 15.19B
-2.17%+6.65%+104.31%+102.15% 13.96B
+1.01%-1.97%+13.53%+19.04% 13.36B
Average -0.63%+1.82%+82.69%+116.32% 25.3B
Weighted average by Cap. -0.59%+1.66%+94.41%+137.99%

Financials

2026 *2027 *
Net sales 1.81B 1.59B 1.47B 1.35B 2.57B 173B 2.62B 17.61B 6.84B 84.79B 6.8B 6.65B 294B 1.89B 1.66B 1.53B 1.41B 2.68B 181B 2.74B 18.41B 7.15B 88.6B 7.1B 6.94B 308B
Net income -64.47M -56.55M -52.21M -48.25M -91.44M -6.17B -93.27M -628M -244M -3.02B -242M -237M -10.49B 101M 88.29M 81.52M 75.33M 143M 9.64B 146M 980M 381M 4.72B 378M 370M 16.37B
Net Debt 961M 843M 778M 719M 1.36B 92.04B 1.39B 9.36B 3.64B 45.04B 3.61B 3.53B 156B 702M 615M 568M 525M 995M 67.17B 1.01B 6.83B 2.65B 32.87B 2.63B 2.58B 114B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
08/07/26 US$54.29 -1.68% 1,706,011
07/07/26 US$55.22 +0.15% 1,719,310
06/07/26 US$55.14 +1.03% 1,747,218
02/07/26 US$54.58 +5.53% 1,653,919
01/07/26 US$51.72 -1.29% 1,638,365
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
54.29USD
Average target price
50.56USD
Spread / Average Target
-6.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock